Kyverna Therapeutics Stock Price, News & Analysis

Kyverna Therapeutics (Nasdaq: KYTX) announced a proposed underwritten public offering of $100,000,000 of common stock on December 15, 2025, with a 30-day underwriter option to purchase up to an additional $15,000,000 of shares at the public offering price, less underwriting discounts and commissions.

All shares will be sold by Kyverna and the offering is being led by J.P. Morgan, Leerink Partners, Morgan Stanley and Wells Fargo Securities. The offering is subject to market and other conditions and will be made pursuant to an effective Form S-3 shelf registration (File No. 333-286180); a preliminary prospectus supplement will be filed with the SEC.

Kyverna Therapeutics (Nasdaq: KYTX) announced positive topline results from the registrational Phase 2 KYSA-8 trial of miv-cel (KYV-101) in stiff person syndrome (SPS) on December 15, 2025. In 26 dosed patients at the Week 16 primary analysis, miv-cel achieved a median 46% improvement in timed 25-foot walk (T25FW) vs baseline (p=0.0002) and 81% of patients exceeded a clinically meaningful 20% T25FW improvement. All secondary endpoints showed highly significant benefits (all p<0.0001).

Safety was manageable with no high-grade CRS or ICANS; Grade 3/4 neutropenia was observed. Kyverna plans a BLA submission in 1H 2026 and will present full data at a 2026 medical conference.

Kyverna Therapeutics (Nasdaq: KYTX) will host a live webcast and conference call on Monday, December 15, 2025 at 8:00 AM ET to review topline results from the registrational Phase 2 KYSA-8 clinical trial evaluating KYV-101 in stiff person syndrome (SPS).

Registration is required to receive a dial-in number and unique PIN; the event can also be accessed via live webcast. Presentation materials will be posted in the Events & Presentations section of Kyverna's investor relations website and an archived replay will be available after the call.

Kyverna Therapeutics (Nasdaq: KYTX) reported Q3 2025 results and a business update, highlighting clinical progress and financing to support late‑stage programs.

Key points: topline SPS (KYSA-8) registrational data now expected in early 2026 with a BLA submission anticipated in 1H 2026; positive interim Phase 2 gMG (KYSA-6) data showing 100% (6/6) patients with mean MG‑ADL −8.0 and QMG −7.7 at 24 weeks and no high‑grade CRS or ICANS; IND for KYV‑102 on track for Q4 2025. Financially, cash and equivalents were $171.1M as of Sept 30, 2025, and Kyverna closed a loan facility up to $150M (initial $25M drawn), supporting a cash runway into 2027.

Kyverna Therapeutics (Nasdaq: KYTX) announced that CEO Warner Biddle will present at the Jefferies Global Healthcare Conference in London on Monday, November 17, 2025 at 1:00 p.m. GMT.

A live webcast will be available via the Investors section of Kyverna's website at ir.kyvernatx.com, and a replay will be posted for approximately 90 days after the conference.

Kyverna Therapeutics (NASDAQ: KYTX) closed a debt facility with Oxford Finance for up to $150 million, drawing an initial $25 million on November 3, 2025. The facility includes an initial tranche structure (totaling up to $150M across four tranches) and matures on October 1, 2030. Kyverna said the financing strengthens liquidity and supports late-stage programs in stiff person syndrome (SPS) and generalized myasthenia gravis (gMG) while accelerating pre-launch work.

Guidance updated: topline registrational SPS data now expected in early 2026 (narrowed from 1H 2026); BLA filing for SPS targeted in 1H 2026; MG Phase 3 enrollment to begin by end of 2025. Additional program readouts and an IND filing for KYV-102 are planned in 2025–2026.

Kyverna Therapeutics (NASDAQ: KYTX) announced positive interim Phase 2 data from the KYSA-6 study of KYV-101 in generalized myasthenia gravis on October 29, 2025.

In six treated patients (data cutoff Oct 3, 2025) a single 1×10^8 CAR+T dose produced mean MG-ADL -8.0 and QMG -7.7 point changes at 24 weeks; 100% (6/6) met co-primary clinical response thresholds and 100% were free of several background immunosuppressive treatments through 24 weeks. Safety showed no Grade ≥3 CRS and no ICANS; one Grade 4 neutropenia resolved to Grade 1 by cutoff.

Kyverna Therapeutics (Nasdaq: KYTX) reported Phase 1 investigator-initiated trial results for KYV-101 in difficult-to-treat rheumatoid arthritis presented at ACR Convergence 2025.

In six ACPA-positive, treatment-refractory patients given a single 1×108 KYV-101 infusion (follow-up 28–175 days), CAR T cells expanded rapidly (peak 14–21 days), B cells were depleted in all patients, and profound reductions in ACPA and RF-IgM were observed. Four of six achieved ACR20 and two achieved ACR50. Safety showed no high-grade CRS or ICANS. These data supported initiation of the randomized Phase 2 portion, with enrollment completed.

Kyverna Therapeutics (Nasdaq: KYTX) will host a conference call on Wednesday, October 29, 2025 at 8:00 AM ET to discuss interim Phase 2 data from the KYSA-6 study of KYV-101 in generalized myasthenia gravis (gMG). The interim data will also be presented at the American Association of Neuromuscular and Electrodiagnostic Medicine Annual Meeting in San Francisco on October 29–November 1, 2025.

The AANEM presentation, titled "Update on the Phase 2 Part of KYSA-6," will be given by Srikanth Muppidi, M.D. on Wednesday, October 29, 2025 at 11:00 AM PT. The call requires registration to receive dial-in and PIN; a live webcast, presentation materials, and archived replay will be available on Kyverna's Investor Relations "Events & Presentations" page at ir.kyvernatx.com.